Boston Scientific to buy Penumbra in $14.5 billion deal
Jan 15 (Reuters) - Boston Scientific said on Thursday it will buy Penumbra in a deal valued at about $14.5 billion to expand its vascular pipeline.
The deal values Penumbra at $374 per share, a premium of about 19.3% to its last close. Penumbra's shares rose over 10% in premarket trading, while Boston's shares fell 4%.
The transaction is expected to be completed in 2026.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shreya Biswas)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Alibaba Slashes Prices To Own The AI Coding Market
2 Lucrative Stocks with Promising Growth and 1 We Steer Clear Of
CryptoRUs’ George Tung Breaks Down Why Prediction Markets Are Beating Polls
Minnesota introduces bill to ban crypto kiosks after wave of elder fraud cases
Trending news
MoreCrypto prices
More
